BioVaxys Technology Corp. (CSE:BIOV)
Canada · Delayed Price · Currency is CAD 0.0700
0.00 (0.00%)
At close: May 6, 2026
BioVaxys Technology Balance Sheet
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jul '25 Jul 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 |
Cash & Equivalents | 0 | 0.21 | 0 | 0.14 | 0.59 | 2.42 |
Cash & Short-Term Investments | 0 | 0.21 | 0 | 0.14 | 0.59 | 2.42 |
Cash Growth | -99.17% | 21579.22% | -99.31% | -76.08% | -75.52% | 958.21% |
Other Receivables | 0.49 | 0.44 | 0.09 | 0.05 | 0.05 | 0.05 |
Receivables | 0.49 | 0.44 | 0.09 | 0.21 | 0.13 | 0.05 |
Prepaid Expenses | 0.9 | 0.65 | 0.02 | 0.36 | 0.15 | 0.59 |
Total Current Assets | 1.39 | 1.3 | 0.11 | 0.71 | 0.87 | 3.06 |
Other Intangible Assets | - | - | - | - | 7.4 | 7.4 |
Total Assets | 1.39 | 1.3 | 0.11 | 0.87 | 8.5 | 10.46 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jul '25 Jul 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 |
Accounts Payable | 2.47 | 1.56 | 2.66 | 1.31 | 0.22 | 0.75 |
Accrued Expenses | 2.42 | 1.6 | 0.83 | 0.33 | 0.11 | 0.15 |
Short-Term Debt | 0.13 | 0.07 | - | - | - | - |
Total Current Liabilities | 5.03 | 3.22 | 3.49 | 1.64 | 0.33 | 0.9 |
Total Liabilities | 5.03 | 3.22 | 3.49 | 1.64 | 0.33 | 0.9 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jul '25 Jul 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 |
Common Stock | 28.59 | 27.04 | 21.99 | 17.05 | 14.76 | 10.75 |
Retained Earnings | -34.55 | -31.25 | -27.3 | -19.61 | -8.02 | -1.56 |
Comprehensive Income & Other | 2.32 | 2.29 | 1.93 | 1.78 | 1.44 | 0.37 |
Shareholders' Equity | -3.64 | -1.92 | -3.37 | -0.77 | 8.18 | 9.56 |
Total Liabilities & Equity | 1.39 | 1.3 | 0.11 | 0.87 | 8.5 | 10.46 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jul '25 Jul 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 |
Total Debt | 0.13 | 0.07 | - | - | - | - |
Net Cash (Debt) | -0.13 | 0.14 | 0 | 0.14 | 0.59 | 2.42 |
Net Cash Growth | - | 14610.95% | -99.31% | -76.08% | -75.52% | 958.21% |
Net Cash Per Share | -0.00 | 0.01 | 0.00 | 0.01 | 0.07 | 0.86 |
Filing Date Shares Outstanding | 29.15 | 29.15 | 22.02 | 11.53 | 9.97 | 8.15 |
Total Common Shares Outstanding | 29.15 | 26.21 | 14.51 | 10.88 | 9.22 | 7.41 |
Working Capital | -3.64 | -1.92 | -3.37 | -0.92 | 0.55 | 2.16 |
Book Value Per Share | -0.12 | -0.07 | -0.23 | -0.07 | 0.89 | 1.29 |
Tangible Book Value | -3.64 | -1.92 | -3.37 | -0.77 | 0.78 | 2.16 |
Tangible Book Value Per Share | -0.12 | -0.07 | -0.23 | -0.07 | 0.08 | 0.29 |